A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Irreversible cell growth arrest, a process termed cellular senescence, is emerging as an intrinsic tumor suppressive mechanism. Oncogene-induced senescence is thought to be invariably preceded by hyperproliferation, aberrant replication, and activation of a DNA damage checkpoint response (DDR), rendering therapeutic enhancement of this process unsuitable for cancer treatment. We previously demonstrated in a mouse model of prostate cancer that inactivation of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (Pten) elicits a senescence response that opposes tumorigenesis. Here, we show that Pten-loss-induced cellular senescence (PICS) represents a senescence response that is distinct from oncogene-induced senescence and can be targeted for cancer therapy. Using mouse embryonic fibroblasts, we determined that PICS occurs rapidly after Pten inactivation, in the absence of cellular proliferation and DDR. Further, we found that PICS is associated with enhanced p53 translation. Consistent with these data, we showed that in mice p53-stabilizing drugs potentiated PICS and its tumor suppressive potential. Importantly, we demonstrated that pharmacological inhibition of PTEN drives senescence and inhibits tumorigenesis in vivo in a human xenograft model of prostate cancer. Taken together, our data identify a type of cellular senescence that can be triggered in nonproliferating cells in the absence of DNA damage, which we believe will be useful for developing a "pro-senescence" approach for cancer prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although initially PTEN loss-induced cellular senescence was not associated with DDR activation40, it was later found to be associated with hyperproliferation, DDR engagement and cellular senescence in vivo41”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this, DDR markers have a limited potential for identifying senescent cells in vivo since DDR independent mechanisms are also capable of inducing senescence via p53/p21WAF1/CIP1 pathway (Alimonti et al., 2010; Freund et al., 2011; Muñoz-Espín et al., 2013; Storer et al., 2013; Salama et al., 2014).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Alimonti et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“pharmacological inhibition of PTEN in prostate cancer that is wild type for TP53, results in the inhibition of tumorigenesis with senescence induction in a human xenograft model 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“TP53 up-regulation upon PTEN inhibition appears to be dependent on mTOR activity, which increases TP53 translation 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“unlike OIS, PICS occurs in the absence of transient hyper-proliferation and a DNA damage response (DDR) 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Small molecule–based reversible reprogramming of cellular lifespan
Won, J., Kim, M. K., Kim, N., Ahn, J. H., Lee, W. G., Kim, S. S., Chang, K.-Y., Yi, Y.-W., & Kim, T. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio800 · Cited by 74
RetractedJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Cited by
Items 101–200 of 372
Shen, W., Liu, L., & Zeng, S. (2018) · Cancer translational medicine · doi:10.4103/ctm.ctm_22_18 · Cited by 98
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Cretella, D., Digiacomo, G., Giovannetti, E., & Cavazzoni, A. (2019) · Cancers · doi:10.3390/cancers11091318 · Cited by 92
Tu, Z., Aird, K. M., Bitler, B. G., Nicodemus, J. P., Beeharry, N., Xia, B., Yen, T. J., & Zhang, R. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.10.010 · Cited by 88
Androgen Depletion Induces Senescence in Prostate Cancer Cells through Down-regulation of Skp2
Pernicová, Z., Slabáková, E., Kharaishvili, G., Bouchal, J., Král, M., Kunická, Z., Machala, M., Kozubík, A., & Souček, K. (2011) · Neoplasia · doi:10.1593/neo.11182 · Cited by 87
Exploiting tumor cell senescence in anticancer therapy
Lee, M., & Lee, J.-S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.2.005 · Cited by 83
Cellular Senescence as a Therapeutic Target for Age-Related Diseases: A Review
Amaya-Montoya, M., Pérez-Londoño, A., Guatibonza-García, V., Vargas-Villanueva, A., & Mendivil, C. O. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01287-0 · Cited by 82
Characterisation of the PTEN inhibitor VO-OHpic
Mak, L. H., Vilar, R., & Woscholski, R. (2010) · Journal of Chemical Biology · doi:10.1007/s12154-010-0041-7 · Cited by 91
Self-citationIs DNA damage indispensable for stress-induced senescence?
Bielak-Żmijewska, A., Mosieniak, G., & Sikora, E. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.004 · Cited by 92
Nowak, D. G., Cho, H., Herzka, T., Watrud, K., DeMarco, D. V., Wang, V. M. Y., Senturk, S., Fellmann, C., Ding, D., Beinortas, T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1113 · Cited by 79
Self-citationWillis, C. M., Nicaise, A. M., Bongarzone, E. R., Givogri, M., Reiter, C. R., Heintz, O., Jellison, E. R., Sutter, P. A., TeHennepe, G., Ananda, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57663-x · Cited by 76
PTEN Inhibition in Human Disease Therapy
Pulido, R. (2018) · Molecules · doi:10.3390/molecules23020285 · Cited by 85
Senescent cells as promising targets to tackle age-related diseases
Prašnikar, E., Borišek, J., & Perdih, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101251 · Cited by 73
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis
Wang, G., Chan, C., Gao, Y., & Lin, H. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10319 · Cited by 83
PTEN inhibitors: An evaluation of current compounds
Spinelli, L., Lindsay, Y. E., & Leslie, N. R. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.09.012 · Cited by 83
Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells
Zhu, Y., Xu, L., Zhang, J., Hu, X., Liu, Y., Yin, H., Lv, T., Zhang, H., Liu, L., An, H., et al. (2013) · Cancer Science · doi:10.1111/cas.12176 · Cited by 71
Liu, Y., Lomeli, I., & Kron, S. J. (2024) · Cells · doi:10.3390/cells13151281 · Cited by 77
A functional genetic screen defines the AKT-induced senescence signaling network
Chan, K. T., Blake, S., Zhu, H., Kang, J., Trigos, A. S., Madhamshettiwar, P. B., Diesch, J., Paavolainen, L., Horvath, P., Hannan, R. D., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0384-8 · Cited by 71
Kustikova, O. S., Schwarzer, A., Stahlhut, M., Brugman, M. H., Neumann, T., Yang, M., Li, Z., Schambach, A., Heinz, N., Gerdes, S., et al. (2012) · Leukemia · doi:10.1038/leu.2012.355 · Cited by 79
Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo
Yu, M., Trobridge, P. A., Wang, Y., Kanngurn, S., Morris, S. M., Knoblaugh, S. E., & Grady, W. M. (2013) · Oncogene · doi:10.1038/onc.2013.102 · Cited by 76
Samarakoon, R., Chitnis, S. S., Higgins, S. P., Higgins, C. E., Krepinsky, J. C., & Higgins, P. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022896 · Cited by 69
Elsallabi, O., Patruno, A., Pesce, M., Cataldi, A., Carradori, S., & Gallorini, M. (2022) · Molecules · doi:10.3390/molecules27030738 · Cited by 67
Wu, X., Xu, R. C., Ouyang, Z.-J., Cheng, Q., Shen, Y., Wu, X., Gu, Y., Xu, Q., & Sun, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083013 · Cited by 67
Khalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 74
Anwar, T., Khosla, S., & Ramakrishna, G. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1189041 · Cited by 66
Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research
Saranyutanon, S., Deshmukh, S. K., Dasgupta, S., Pai, S. G., Singh, S., & Singh, A. P. (2020) · Cancers · doi:10.3390/cancers12092651 · Cited by 85
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer
Ahmad, I., Patel, R., Singh, L. B., Nixon, C., Seywright, M. M., Barnetson, R. J., Brunton, V. G., Muller, W. J., Edwards, J., Sansom, O. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101263108 · Cited by 70
Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis
Walton, C. C., Begelman, D., Nguyen, W., & Andersen, J. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00129 · Cited by 62
Cufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Quirantes, R., Segura-Carretero, A., Micol, V., Joven, J., Bosch-Barrera, J., Del Barco, S., Martin-Castillo, B., et al. (2012) · Cell Cycle · doi:10.4161/cc.11.6.19665 · Cited by 61
Zou, M., Baitei, E. Y., Al‐Rijjal, R. A., Parhar, R. S., Al-Mohanna, F. A., Kimura, S., Pritchard, C. A., BinEssa, H. A., Alzahrani, A. S., Al‐Khalaf, H. H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.253 · Cited by 63
Senescence under appraisal: hopes and challenges revisited
Davan-Wetton, C. S. A., Pessolano, E., Perretti, M., & Montero‐Melendez, T. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03746-x · Cited by 64
Śnietura, M., Jaworska, M., Młynarczyk-Liszka, J., Goraj-Zając, A., Pigłowski, W., Lange, D., Woźniak, G., Nowara, E., & Suwiński, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033396 · Cited by 66
PTEN: A yin-yang master regulator protein in health and disease
Pulido, R. (2015) · Methods · doi:10.1016/j.ymeth.2015.02.009 · Cited by 70
Cellular senescence as a possible link between prostate diseases of the ageing male
Fiard, G., Stavrinides, V., Chambers, E. S., Heavey, S., Freeman, A., Ball, R., Akbar, A. N., & Emberton, M. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00496-8 · Cited by 62
Bikkavilli, R. K., Avasarala, S., Scoyk, M. M. V., Arcaroli, J. J., Brzezinski, C. R., Zhang, W., Edwards, M. G., Rathinam, M. K. K., Zhou, T., Tauler, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.2 · Cited by 56
Aird, K. M., Li, H., Xin, F., Konstantinopoulos, P. A., & Zhang, R. (2013) · Cell Cycle · doi:10.4161/cc.26953 · Cited by 59
A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis
Zhang, B., Chen, H., Zhang, L., Dakhova, O., Zhang, Y., Lewis, M. T., Creighton, C. J., Ittmann, M., & Li, X. (2013) · Oncogene · doi:10.1038/onc.2013.281 · Cited by 52
Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers
Llanos, S., Garcia-Pedrero, J. M., Morgado-Palacin, L., Rodrigo, J. P., & Serrano, M. (2016) · Nature Communications · doi:10.1038/ncomms10438 · Cited by 52
PTEN controls β‐cell regeneration in aged mice by regulating cell cycle inhibitor p16ink4a
Zeng, N., Yang, K., Bayan, J., He, L., Aggarwal, R., Stiles, J. W., Hou, X., Medina, V., Abad, D., Palian, B. M., et al. (2013) · Aging Cell · doi:10.1111/acel.12132 · Cited by 49
The paradox of senescent-marker positive cancer cells: challenges and opportunities
O’Sullivan, E. A., Wallis, R., Mossa, F., & Bishop, C. L. (2024) · npj Aging · doi:10.1038/s41514-024-00168-y · Cited by 62
Cr(VI) induces premature senescence through ROS-mediated p53 pathway in L-02 hepatocytes
Zhang, Y., Zhang, Y., Zhong, C., & Xiao, F. (2016) · Scientific Reports · doi:10.1038/srep34578 · Cited by 58
Diegel, C. R., Cho, K. R., El‐Naggar, A. K., Williams, B. O., & Lindvall, C. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1758 · Cited by 51
ZRF1 is a novel S6 kinase substrate that drives the senescence programme
Barilari, M., Bonfils, G., Treins, C., Koka, V., Villeneuve, D. D., Fabrega, S., & Pende, M. (2017) · The EMBO Journal · doi:10.15252/embj.201694966 · Cited by 55
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis
Limberger, T., Schlederer, M., Trachtová, K., Alonso, I. G. D. L. F., Yang, J., Högler, S., Sternberg, C., Bystrý, V., Oppelt, J., Tichý, B., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01542-8 · Cited by 52
Antitumor mechanisms when pRb and p53 are genetically inactivated
Zhu, L., Lu, Z., & Zhao, H.-T. (2014) · Oncogene · doi:10.1038/onc.2014.399 · Cited by 65
Cheng, X. F., Yao, X., Xu, S., Pan, J., Yu, H., Bao, J., Guan, H., Lu, R., & Zhang, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.074 · Cited by 50
Autoimmunity checkpoints as therapeutic targets in B cell malignancies
Müschen, M. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.111 · Cited by 51
Kalathur, M., Toso, A., Chen, J., Revandkar, A., Danzer-Baltzer, C., Guccini, I., Alajati, A., Sarti, M., Pinton, S., Brambilla, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms8227 · Cited by 44
Self-citationSecretome of Human Fetal Mesenchymal Stem Cell Ameliorates Replicative Senescence
Wang, B., Lee, W., Huang, B., Zhang, J., Wu, T., Jiang, X., Wang, C. C., & Li, G. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0079 · Cited by 50
The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein
Chen, M., Nowak, D. G., Narula, N., Robinson, B. D., Watrud, K. E., Ambrico, A. J., Herzka, T. M., Zeeman, M. E., Minderer, M., Zheng, W., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201604025 · Cited by 45
Self-citationCDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati, A., D’Ambrosio, M., Troiani, M., Mosole, S., Pellegrini, L., Chen, J., Revandkar, A., Bolis, M., Theurillat, J.-P. P., Guccini, I., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131133 · Cited by 47
Self-citationPTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo
Parisotto, M., Grelet, E., El Bizri, R., Dai, Y., Terzic, J., Eckert, D., Gargowitsch, L., Bornert, J.-M., & Metzger, D. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171207 · Cited by 43
“As we demonstrate here that PTEN loss–induced cell senescence in prostate epithelial cells is mediated at least in part by replication stress after a phase of enhanced proliferation in vivo, this type of senescence resembles other types of senescence, in particular OIS, in contrast to previous conclusions drawn from o…”
BackgroundResultInfluentialThe Chemical Biology of Phosphoinositide 3‐Kinases
Wymann, M. P., & Schultz, C. (2012) · ChemBioChem · doi:10.1002/cbic.201200089 · Cited by 44
Wang, Z., Li, Y., Wu, D., Yu, S., Wang, Y., & Chan, F. L. (2019) · Oncogene · doi:10.1038/s41388-019-1080-3 · Cited by 52
Neutrophils: Critical components in experimental animal models of cancer
Hagerling, C., & Werb, Z. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.02.003 · Cited by 44
Age-Related Lysosomal Dysfunctions
Guerrero‐Navarro, L., Jansen‐Dürr, P., & Cavinato, M. S. (2022) · Cells · doi:10.3390/cells11121977 · Cited by 53
Cellular senescence in tissue repair: every cloud has a silver lining
Yun, M. H. (2018) · The International Journal of Developmental Biology · doi:10.1387/ijdb.180081my · Cited by 41
The equilibrium of tumor suppression: DUBs as active regulators of PTEN
Christine, A., Park, M. K., Song, S. J., & Song, M. S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00887-w · Cited by 44
Activatable senoprobes and senolytics: Novel strategies to detect and target senescent cells
Morsli, S., Doherty, G. J., & Muñoz-Espín, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111618 · Cited by 42
Brel, V., Annereau, J., Vispé, S., Kruczynski, A., Bailly, C., & Guilbaud, N. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.028 · Cited by 44
Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence
Shin, J., Yang, J., Lee, J. C., & Baek, K. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.014 · Cited by 44
Shifting senescence into quiescence by turning up p53
Serrano, M. (2010) · Cell Cycle · doi:10.4161/cc.9.21.13785 · Cited by 39
Kokal, M., Mirzakhani, K., Pungsrinont, T., & Baniahmad, A. (2020) · Cancers · doi:10.3390/cancers12071833 · Cited by 46
A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells
Augello, G., Puleio, R., Emma, M. R., Cusimano, A., Loria, G. R., McCubrey, J. A., Montalto, G., & Cervello, M. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1138183 · Cited by 42
Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies
Fakhri, S., Moradi, S. Z., DeLiberto, L. K., & Bishayee, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114989 · Cited by 42
Pharmacological Activation of p53 in Cancer Cells
Athar, M., Elmets, C. A., & Kopelovich, L. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222595 · Cited by 47
Ketkar, M., Desai, S., Rana, P., Thorat, R. A., Epari, S., Dutt, A., & Dutt, S. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae134 · Cited by 43
Aging and the Biological Response to Liver Injury
Marzioni, M., Pinto, C., Ninfole, E., Gaggiano, L., Benedetti, A., & Maroni, L. (2020) · Seminars in Liver Disease · doi:10.1055/s-0039-3402033 · Cited by 36
Biomarkers in the path from cellular senescence to frailty
Zampino, M., Ferrucci, L., & Semba, R. D. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110750 · Cited by 42
Clark, O., Daga, S., & Stoker, A. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.014 · Cited by 37
Disruptive chemicals, senescence and immortality
Carnero, A., Blanco-Aparicio, C., Kondoh, H., Lleonart, M. E., Martinez-Leal, J. F., Mondello, C., Scovassi, A. I., Bisson, W. H., Amedei, A., Roy, R., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv029 · Cited by 29
mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels
Goudarzi, K. M., Nistér, M., & Lindström, M. S. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.955743 · Cited by 35
Role of PTEN-less in cardiac injury, hypertrophy and regeneration
Liang, T., Gao, F., & Chen, J. (2021) · Cell Regeneration · doi:10.1186/s13619-021-00087-3 · Cited by 33
Zhu, H., Chan, K. T., Huang, X., Cerra, C., Blake, S., Trigos, A., Anderson, D., Creek, D. J., Souza, D. P. D., Wang, X., et al. (2022) · eLife · doi:10.7554/elife.71929 · Cited by 36
Macià, A., Vaquero, M., Gou-Fàbregas, M., Castelblanco, E., Valdivielso, J. M., Anerillas, C., Mauricio, D., Matías‐Guiu, X., Ribera, J., & Encinas, M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.161 · Cited by 38
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP
Paul, P. J., Raghu, D., Chan, A.-L., Gulati, T., Lambeth, L. S., Takano, E. A., Herold, M. J., Hagekyriakou, J., Vessella, R. L., Fedele, C. G., et al. (2016) · Oncogene · doi:10.1038/onc.2016.159 · Cited by 32
Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1
Duan, L., Perez, R. E., Hansen, M., Gitelis, S., & Maki, C. G. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.961876 · Cited by 33
Scaglioni, P. P., Rabellino, A., Yung, T. M., Bernardi, R., Choi, S., Konstantinidou, G., Nardella, C., Cheng, K., & Pandolfi, P. P. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200233 · Cited by 34
Self-citationMechanisms of oncogene-induced genomic instability
Graziano, S., & Gonzalo, S. (2016) · Biophysical Chemistry · doi:10.1016/j.bpc.2016.11.008 · Cited by 37
Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy
Kennedy, A. L., Adams, P. D., & Morton, J. P. (2011) · Small GTPases · doi:10.4161/sgtp.2.5.17367 · Cited by 37
Poovassery, J. S., Kang, J. C., Kim, D., Ober, R. J., & Ward, E. S. (2014) · International Journal of Cancer · doi:10.1002/ijc.29378 · Cited by 35
Hoff, U., Markmann, D., Thurn-Valassina, D., Nieminen-Kelhä, M., Erlangga, Z., Schmitz, J., Bräsen, J. H., Budde, K., Melk, A., & Hegner, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266319 · Cited by 34
Chojak, R., Fares, J., Petrosyan, E., & Lesniak, M. S. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04387-3 · Cited by 35
Narlik‐Grassow, M., Blanco‐Aparicio, C., Cecilia, Y., Pérez, M., Muñoz-Galván, S., Cañamero, M., & Carnero, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060277 · Cited by 31
PTEN Mouse Models of Cancer Initiation and Progression
Lee, Y.-R., & Pandolfi, P. P. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037283 · Cited by 32
Self-citationKawakami, I., Yoshino, H., Fukumoto, W., Tamai, M., Okamura, S., Osako, Y., Sakaguchi, T., Inoguchi, S., Matsushita, R., Yamada, Y., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.068 · Cited by 28
Cell Senescence and Central Regulators of Immune Response
Lunin, S. M., Novoselova, E. G., Glushkova, O. V., Parfenyuk, S. B., Novoselova, T. V., & Khrenov, M. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084109 · Cited by 31
de Assis, L. V. M., & Isoldi, M. C. (2013) · Tumor Biology · doi:10.1007/s13277-013-1210-4 · Cited by 32
Cellular Senescence as a Possible Mechanism for Halting Progression of Keloid Lesions
Varmeh, S., Egia, A., McGrouther, D. A., Tahan, S. R., Bayat, A., & Pandolfi, P. P. (2011) · Genes & Cancer · doi:10.1177/1947601912440877 · Cited by 31
Self-citationToso, A., Mitri, D. D., & Alimonti, A. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994380 · Cited by 35
Self-citationSenescence and Cancer: Role of Nitric Oxide (NO) in SASP
Mabrouk, N., Ghione, S., Laurens, V., Plenchette, S., Bettaïeb, A., & Paul, C. (2020) · Cancers · doi:10.3390/cancers12051145 · Cited by 29
Role of Ubiquitination in PTEN Cellular Homeostasis and Its Implications in GB Drug Resistance
Qin, X., Ali, S., Liu, L., Li, Y., Liu, X., Zhang, L., & Dong, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01569 · Cited by 31
Wang, Z., Li, Y., Wu, D., Yu, S., Wang, Y., & Chan, F. L. (2020) · Oncogene · doi:10.1038/s41388-020-1290-8 · Cited by 27
Never-ageing cellular senescence
Öğrünç, M., & di Fagagna, F. D. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.003 · Cited by 37
Kovalenko, T. F., Morozova, K. V., Ozolinya, L. A., Лапина, И. А., & Patrushev, L. I. (2018) · Acta Naturae · doi:10.32607/20758251-2018-10-1-43-50 · Cited by 32
Nuclear PTEN’s Functions in Suppressing Tumorigenesis: Implications for Rare Cancers
Langdon, C. G. (2023) · Biomolecules · doi:10.3390/biom13020259 · Cited by 29
p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia
Short, S. P., Kondo, J., Smalley-Freed, W. G., Takeda, H., Dohn, M. R., Powell, A. E., Carnahan, R. H., Washington, M. K., Tripathi, M. K., Payne, D. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci77217 · Cited by 26
Targeting PTEN using small molecule inhibitors
Mak, L. H., & Woscholski, R. (2015) · Methods · doi:10.1016/j.ymeth.2015.02.007 · Cited by 29
Self-citationLiu, Y., Hawkins, O. E., Vilgelm, A. E., Pawlikowski, J. S., Ecsedy, J., Sosman, J. A., Kelley, M. C., & Richmond, A. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0293 · Cited by 29
Unraveling Adipocytes and Cancer Links: Is There a Role for Senescence?
Wu, Q., Li, B., Sun, S., & Sun, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00282 · Cited by 24
Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy
Yang, H., Liu, D., Qiu, L., Wang, R., Zhang, C., Yu, D., Zhong, Q., Yuki, N., Song, Z., Zhu, Τ., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02459-8 · Cited by 38
Metadata
- Authors
- Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., Rosivatz, E., Woscholski, R., Cognetti, F., Scher, H. I., & Pandolfi, P. P.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Cincinnati (US)
- Imperial College London (GB)
- Instituto Nazionale Tumori Regina Elena (IT)
- Corresponding author
- Pandolfi, Pier Paolo
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-03-01
- Volume
- 120
- Issue
- 3
- Pages
- 681-693
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2827955
- OpenAlex
- W2005250235
- Cited by
- 374
- References
- 46
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 23 · 2023: 12 · 2022: 24 · 2021: 18 · 2020: 30 · 2019: 17 · 2018: 27 · 2017: 17 · 2016: 20 · 2015: 20 · 2014: 28 · 2013: 25 · 2012: 27
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- American-Italian Cancer Foundation
- Associazione Italiana di Oncologia Medica
- National Institutes of Health
- National Cancer Institute (R01CA137050)
- National Institute on Minority Health and Health Disparities (R01MD004038)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, PTEN inactivation, prostate cancer, tumor suppression, DNA damage response, non-proliferating cells, tumor xenografts
- MeSH terms
- Animals, Disease Models, Animal, DNA Damage, Embryo, Mammalian, Fibroblasts, Humans, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Biosynthesis, Transplantation, Heterologous, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Cellular Senescence, Mice, Knockout, Cell Line, Tumor, Cell Proliferation, PTEN Phosphohydrolase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.